Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes

Circulation Journal

Volumn 77, Issue 5, 2013, Pages 1337-1344

  Matsubara, Junichi ^a,b   Sugiyama, Seigo ^a   Akiyama, Eiichi ^a   Iwashita, Satomi ^a   Kurokawa, Hirofumi ^a   Ohba, Keisuke ^a   Maeda, Hirofumi ^a   Fujisue, Koichiro ^a   Yamamoto, Eiichiro ^a   Kaikita, Koichi ^a   Hokimoto, Seiji ^a,b   Jinnouchi, Hideaki ^b,c,d   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Department of Cardiovascular Clinical and Translational Research ^*  (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^d Jinnouchi Hospital   (Japan)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Endothelial function; Inflammation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; OMEGA 3 FATTY ACID; SITAGLIPTIN; SULFONYLUREA;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG DOSE REDUCTION; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HUMAN; HYPEREMIA; MALE; TONOMETRY;

AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION MEDIATORS; LINEAR MODELS; LOGISTIC MODELS; MALE; MANOMETRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; PYRAZINES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84876780409     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1168     Document Type: Article

References (30)

1. Saito I. Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. Circ J 2012; 76: 1066-1073.
2. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-126.
3. Vita JA, Keaney JF Jr. Endothelial function: A barometer for cardiovascular risk? Circulation 2002; 106: 640-642.
4. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
5. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002; 8: 1235-1242.
6. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
7. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.
8. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-E1215.
9. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21: 1125-1135.
10. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein e-deficient mice. J Am Coll Cardiol 2012; 59: 265-276.
11. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
12. Matsuzawa Y, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Konishi M, et al. Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol 2010; 55: 1688-1696.
13. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008; 117: 2467-2474.
14. Selamet Tierney ES, Newburger JW, Gauvreau K, Geva J, Coogan E, Colan SD, et al. Endothelial pulse amplitude testing: Feasibility and reproducibility in adolescents. J Pediatr 2009; 154: 901-905.
15. Bonetti PO, Barsness GW, Keelan PC, Schnell TI, Pumper GM, Kuvin JT, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003; 41: 1761-1768.
16. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
17. Ahanchi SS, Tsihlis ND, Kibbe MR. The role of nitric oxide in the pathophysiology of intimal hyperplasia. J Vasc Surg 2007; 45(Suppl A): A64-A73.
18. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
19. Maron BA, Michel T. Subcellular localization of oxidants and redox modulation of endothelial nitric oxide synthase. Circ J 2012; 76: 2497-2512.
20. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998; 97: 2494-2498.
21. Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010; 325: 26-35.
22. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 1335-1343.
23. Zaruba MM, Theiss HD, Vallaster M, Mehl U, Brunner S, Fischer R, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009; 4: 313-323.
24. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
25. Fadini GP, Agostini C, Sartore S, Avogaro A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 2007; 194: 46-54.
26. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: Possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33: 1607-1609.
27. Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 2012; 97: 3333-3341.
28. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003; 146: 168-174.
29. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44: 2137-2141.
30. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: Role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012; 35: 2076-2082.